Glucose homeostasis changes and pancreatic β-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus
Nefrologia. 2015;35(3):264-72.
doi: 10.1016/j.nefro.2015.05.007.
Epub 2015 Jun 27.
[Article in
English,
Spanish]
Affiliations
- 1 Unidad de Investigación, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, España.
- 2 Unidad de Investigación, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, España. Electronic address: estebanporrini72@hotmail.com.
- 3 Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, España.
- 4 Laboratorio central, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, España.
- 5 Centro para la Investigación Biomédica de Canarias, Universidad de La Laguna, San Cristóbal de La Laguna, Santa Cruz de Tenerife, España.
- 6 Servicio de Nefrología, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, España.
Abstract
Background:
Switching to cyclosporine A may result in a reversion of tacrolimus-induced diabetes mellitus. However, mechanisms underlying such a reversion are still unknown.
Methods:
Obese Zucker rats were used as a model for tacrolimus-induced diabetes mellitus. A cohort of 44 obese Zucker rats received tacrolimus for 11 days (0.3mg/kg/day) until diabetes development; then: (a)22 rats were euthanized at day 12 and were used as a reference group (tacrolimus-day 12), and (b)22 rats on tacrolimus were shifted to cyclosporin (2.5mg/kg/day) for 5 days (tacrolimus-cyclosporin). An additional cohort of 22 obese Zucker rats received the vehicle for 17 days and were used as a control group. All animals underwent an intraperitoneal glucose tolerance test at the end of the study.
Results:
β-cell proliferation, apoptosis and Ins2 gene expression were evaluated. Compared to rats in tacrolimus-day 12 group, those in tacrolimus-cyclosporin group showed a significant improvement in blood glucose levels in all assessment points in intraperitoneal glucose tolerance test. Diabetes decreased from 100% in tacrolimus-day 12 group to 50% in tacrolimus-cyclosporin group. Compared to tacrolimus-day 12 group, rats in tacrolimus-cyclosporin group showed an increased β-cell proliferation, but such an increase was lower than in rats receiving the vehicle. Ins2 gene expressions in rats receiving tacrolimus-cyclosporin and rats receiving the vehicle were comparable.
Conclusion:
An early switch from tacrolimus to cyclosporin in tacrolimus-induced diabetes mellitus resulted in an increased β-cell proliferation and reversion of diabetes in 50% of cases.
Keywords:
Ciclosporina-A; Cyclosporin A; Diabetes postrasplante; Post-transplant diabetes mellitus; Tacrolimus.
Copyright © 2015 The Authors. Published by Elsevier España, S.L.U. All rights reserved.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Apoptosis / drug effects
-
Calcineurin Inhibitors / pharmacology
-
Calcineurin Inhibitors / toxicity*
-
Carbohydrate Metabolism / drug effects*
-
Cell Division / drug effects
-
Cyclosporine / pharmacology*
-
Diabetes Mellitus, Experimental / chemically induced*
-
Diabetes Mellitus, Experimental / metabolism
-
Diabetes Mellitus, Experimental / pathology
-
Drug Substitution
-
Glucose / metabolism*
-
Glucose Tolerance Test
-
Homeostasis / drug effects
-
Insulin Resistance
-
Insulin-Secreting Cells / cytology
-
Insulin-Secreting Cells / drug effects*
-
Obesity / complications
-
Obesity / metabolism
-
Proinsulin / biosynthesis
-
Proinsulin / genetics
-
Rats
-
Rats, Zucker
-
Tacrolimus / toxicity*
Substances
-
Calcineurin Inhibitors
-
Cyclosporine
-
Proinsulin
-
Glucose
-
Tacrolimus